Martin Shkreli (, born March 17, 1983) is an American businessman and former hedge fund manager. He is the co-founder of the hedge funds Elea Capital, MSMB Capital Management, MSMB Healthcare, co-founder and former chief executive officer (CEO) of the biotechnology firm Retrophin, and founder and former CEO of Turing Pharmaceuticals. Shkreli is also the CEO of start-up software company Gödel Systems, which he founded in August 2016.In September 2015, Shkreli received widespread criticism when Turing obtained the manufacturing license for the antiparasitic drug Daraprim and raised its price by a factor of 56 (from US$13.5 to US$750 per pill), leading him to be referred to as "the most hated man in America" and "pharma bro". Wikipedia